Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418463 | 1.00 | BIRC2 (0.47) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2422071 | 1.00 | BIRC2 (0.47) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL18150389 | 0.98 | BIRC2 (0.46) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL4223891 | 0.98 | BIRC2 (0.46) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL15105232 | 0.88 | BIRC2 (0.40) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL15105233 | 0.88 | BIRC2 (0.40) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL28120270 | 0.84 | BIRC2 (0.49) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL28048803 | 0.84 | BIRC2 (0.49) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL27957087 | 0.84 | BIRC2 (0.49) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL190024 | 0.83 | BIRC2 (0.47) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551867-B | Fused tricyclic compounds, pharmaceutical compositions and uses thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-115551867-A | Fused tricyclic compound, pharmaceutical composition and application thereof | 劲方医药科技(上海)有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2013163466-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| US-8318746-B2 | Nitrogen-containing five-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | WU WENXUE | 2010-09-30 | — | — | US | disclosed |
| US-7745626-B2 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2149550-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | NEUROGEN CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-7326709-B2 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| CN-1045972-A | 5-replaces-1,4-dihydro-4-oxo-naphthyridine-3-carboxylic acid (ester) antimicrobial drug | BRISTOL MYERS SQUIBB CO (US) | 1990-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | GABBR1, GABBR2, GABRA4 | BIRC2 4799/4885HRH4 453/4885CHRNB2 108/4885 |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | BIRC2 4302/4885HRH4 85/4885CHRNB2 450/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | BIRC2 1348/4885HRH4 1600/4885CHRNB2 4797/4885 |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | BIRC2 3186/4885HRH4 3845/4885CHRNB2 4825/4885 |
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | ALKBH5, AZI2, PNMT | BIRC2 1055/4885HRH4 1756/4885CHRNB2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.